The Role of Inflammatory Proteins in Anti-Glucocorticoid Therapy for Treatment-Resistant Depression.

ABSTRACT:

Background

Optimising treatments for patients with treatment-resistant depression (TRD) is key to reducing the burden of this severe illness. The anti-glucocorticoid medication metyrapone has mixed evidence supporting a role as a possible augmentation treatment in TRD. The degree of treatment resistance in depression has been associated prospectively and retrospectively with elevated inflammation, and inflammatory activity may influence responses to antidepressant treatments.

Aims

To investigate whether levels of pro-inflammatory cytokines are associated with clinical outcomes to metyrapone or placebo.

Methods

A double-blind RCT randomised patients with TRD to 3 weeks of placebo or metyrapone augmentation to ongoing serotonergic antidepressants. No benefit of metyrapo

SUBMITTER: Strawbridge R 

PROVIDER: S-EPMC7920038 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature